Select Topic:
Browse by Series:

Combinations May Be the Future in HCC

Insights From: Richard Finn, MD, David Geffen School of Medicine at UCLA
Published: Tuesday, Sep 10, 2019



Key Takeaways: 

Novel studies looking at combining locoregional therapies with newer immuno-oncology agents for early-stage hepatocellular carcinoma (HCC).

Evolving the treatment landscape of hepatocellular carcinoma (HCC) by moving effective systemic therapy combinations into the frontline.

Improving overall survival in patients with advanced or metastatic hepatocellular carcinoma by combining immunotherapies with tyrosine kinase inhibitors (TKIs) or novel antibodies.

 
Slider Left
Slider Right


Key Takeaways: 

Novel studies looking at combining locoregional therapies with newer immuno-oncology agents for early-stage hepatocellular carcinoma (HCC).

Evolving the treatment landscape of hepatocellular carcinoma (HCC) by moving effective systemic therapy combinations into the frontline.

Improving overall survival in patients with advanced or metastatic hepatocellular carcinoma by combining immunotherapies with tyrosine kinase inhibitors (TKIs) or novel antibodies.

 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x